Passion for Innovation. Compassion for Patients.™ Daiichi Sankyo Europe GmbH

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

Gastric Cancer

We seek to make a difference in gastric cancer treatment

Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease; there were approximately one million new cases reported in 2020 and more than 768,000 deaths.2,4 In the U.S., it is estimated that 27,600 new cases of gastric cancer were diagnosed in 2020 and more than 11,000 people died from the disease.5

There are different biomarkers for gastric cancer like the VEGF family, E-cadherin, PD-L1 and PD-L2, FGFR or mTOR that can help select cancer treatment. Approximately one in five gastric cancers are HER2 positive.3 HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumours including breast, gastric, lung and colorectal cancer. Gastric cancer is usually diagnosed in the advanced stage, but even when diagnosed in earlier stages of the disease, the survival rate remains modest.1

We are deeply committed to transforming the lives of people living with stomach cancer because we want to enable patients – whether they are a partner, a parent, or a friend – to experience moments in life that matter.

References

1 Curea F.G, et al. Cancer Biotherapy & Radiopharmaceuticals. 2017;32 (10).
2 American Cancer Society. Stomach Cancer: Stomach Cancer Survival Rates. October 2020.
3 American Cancer Society. Targeted Therapies for Stomach Cancer. October 2020.
4 Global Cancer Observatory. World. Accessed January 2021.
5 National Cancer Institute. https://seer.cancer.gov/statfacts/html/stomach.html.  Accessed January 2021.